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Chromosome Rearrangements with a Suggested
Next-Generation Cytogenetic Nomenclature
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Sara Althari,2 James F. Gusella,3,4,5,6,7 Michael E. Talkowski,3,5,6,7 and Cynthia C. Morton1,2,5,6,*
With recent rapid advances in genomic technologies, precise delineation of structural chromosome rearrangements at the nucleotide
level is becoming increasingly feasible. In this era of ‘‘next-generation cytogenetics’’ (i.e., an integration of traditional cytogenetic tech-
niques and next-generation sequencing), a consensus nomenclature is essential for accurate communication and data sharing.
Currently, nomenclature for describing the sequencing data of these aberrations is lacking. Herein, we present a system called Next-
Gen Cytogenetic Nomenclature, which is concordant with the International System for Human Cytogenetic Nomenclature (2013).
This system starts with the alignment of rearrangement sequences by BLAT or BLAST (alignment tools) and arrives at a concise and
detailed description of chromosomal changes. To facilitate usage and implementation of this nomenclature, we are developing a
program designated BLA(S)T Output Sequence Tool of Nomenclature (BOSToN), a demonstrative version of which is accessible online.
A standardized characterization of structural chromosomal rearrangements is essential both for research analyses and for application in
the clinical setting.Introduction
It has been over half a century since the human chromo-
some number was reported to be 46 and not 48,1 an event
that vitalized interest in human cytogenetics and subse-
quently required an international system of nomenclature
to be developed. Therefore, a study group at the ‘‘Denver
Conference’’ (1960) proposed a system that became the
foundation of human cytogenetic nomenclature.2 Soon
thereafter, human chromosome bands were identified,3,4
and a meeting held in Paris in 1971 yielded a significant
document in the annals of human cytogenetics by recom-
mending a classification system for chromosome bands
and by providing nomenclature for structural chromo-
some rearrangements.5 In 1978, previous international
conference reports were reviewed and combined into a
document titled ‘‘An International System for Human
Cytogenetic Nomenclature (1978),’’ abbreviated as ISCN
1978 by the International Standing Committee on Human
Cytogenetic Nomenclature.6
Rapid growth in the knowledge of constitutional and
acquired chromosome aberrations after improvements in
cytogenetic techniques (including high-resolution band-
ing, in situ hybridization, and microarrays) has necessi-
tated revisions to the ISCN, published subsequently in
1981,7 1985,8 1991,9 1995,10 2005,11 2009,12 and most
recently in 2013.13 ISCN 2013 provides instruction on a
variety of issues arising from new molecular genetic meth-
odologies (e.g., chromothripsis and duplication, using a
genome build when describing microarray results, nomen-1Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham a
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The Amclature for targeted quantitative assays). With the excep-
tion of microarray nomenclature, which can describe
unbalanced copy-number variations (CNVs), nomencla-
ture for structural chromosome rearrangements is limited
to the description of chromosome-band levels and in situ
hybridization probes. Therefore, a consensus system for
the description of chromosomal abnormalities at the level
of nucleotide resolution achievable routinely by next-gen-
eration sequencing methods has yet to be addressed.
Sequencing breakpoints of structural chromosome
rearrangements has been possible since the 1980s.14,15
However, timely localization of these aberrations to the
nucleotide level in a genome-wide context became feasible
only with recent improvements in massively parallel
sequencing technologies, yet it promises to revolutionize
the field of cytogenetics.16–19 Historical methods that
have been used in cytogenetics are unable to resolve struc-
tural rearrangements to the nucleotide level, which makes
it difficult to analyze the actual pathological burden. Spe-
cific identification of disrupted genomic region(s) is critical
in diagnosis and management of constitutional and
acquired rearrangements, especially as annotation of the
human genome accelerates.20–31 The ability to map break-
points precisely is the foundation of the Developmental
Genome Anatomy Project (DGAP), through which more
than 100 subjects with apparently balanced chromosome
rearrangements and congenital disorders have been
sequenced, revealing a wide variety of genes disrupted
and dysregulated in human development. Throughout
these DGAP studies, it has become increasingly clear thatnd Women’s Hospital, Boston, MA 02115, USA; 2Department of Pathology,
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Figure 1. Schematic Diagrams of Simple Chromosomal Aberrations Show the Number of Breakpoints and Rearrangements
(A and B) Four breakpoints on each side of the break (left) and reunion (middle) and two rearrangements (right) in a simple translocation
(A) and an inversion (B).
(C) Six breakpoints (left, middle) and three rearrangements (right) in a simple insertion.
(D) Two breakpoints (left, middle) and one rearrangement (right) in a simple deletion.additional nomenclature guidance is needed for accurate
and full description of these chromosome aberrations.
Currently, most reports of sequencing results provide
nucleotide numbers of the breakpoints in various formats
based upon the reference-genome sequence align-
ment.20–29 However, additional important characteristics
of the rearrangement—including reference-genome identi-
fication, chromosome-band level, direction of the
sequence, homology, repeats, and nontemplated
sequence—are not typically described.
Terminology that can be understood universally among
scientists and clinicians with optimal description will
enhance communication of sequencing data of such
rearrangements. Thus, we propose Next-Gen Cytogenetic
Nomenclature, a set of recommendations elucidated from
sequencing results and analogous with ISCN 2013 for
structural chromosome rearrangements, and use examples
largely derived from previously published DGAP cases.
These recommendations can potentially address all of the
above-mentioned characteristics of structural rearrange-
ments in a systematic approach.Material and Methods
The UCSC Genome Browser32 is used for aligning rearrangement
sequences obtained through capillary sequencing confirmation696 The American Journal of Human Genetics 94, 695–709, May 1, 2of constitutional and neoplastic chromosome aberrations after
next-generation sequencing.19 This website provides BLAST (Basic
Local Alignment Search Tool33)-Like Alignment Tool (BLAT) for
sequence alignment.34 Using this tool for manual interpretation
of the rearrangements has several advantages, including being
faster than BLASTand having a direct link into the UCSC Genome
Browser.35 Screenshots from the website are provided according to
the website guidelines titled ‘‘Citing the UCSC Browser in a
Publication or Web Page’’ (Figures 2, S2–S4, S6–S8, S10–S12, S14,
S15, S17–S20, S22–S25, S28–S32, S36–S39, S41–S43, S47, S50,
and S53, available online).When applicable, sample cases herein
are referred to by their DGAP identification numbers.
To facilitate explanations throughout this document, we define
the terms breakpoint and rearrangement sequence below.014Breakpoint: the nucleotides on each side of the break (Figure 1,
left) and reunion (Figure 1, middle).
Rearrangement sequence: the sequence that encompasses rear-
ranged breakpoints and, therefore, the breakage and reunion
(::) (Figure 1, right). In other words, this sequence is the junc-
tion of DNA sequences that are noncontiguous in the reference
sequence and that occur as a result of the structural alteration
of the chromosome(s). As described in ISCN 2013, structurally
altered chromosomes may be referred to as derivative (der)
chromosomes, among other terms and symbols.On the basis of these definitions, there are four breakpoints and
two rearrangements in a ‘‘simple case’’ with a translocation or an
Figure 2. BLAT Alignment of a Rearrangement Sequence from a Hypothetical Case with a Simple Translocation of
t(1;8)(q23.3;q12.2)
There are four breakpoints and two rearrangements (left). Rearrangement_A (on der(1)) is submitted to ‘‘BLAT Search Genome,’’ and ac-
curate alignments are chosen as shown in the flowchart (right). The same process is then applied to Rearrangement_B (data not shown).inversion (Figure 1A and 1B); six breakpoints and three rearrange-
ments in a simple insertion case (Figure 1C); and two breakpoints
and one rearrangement in a simple deletion case (Figure 1D).
Likewise, complex cases with more rearrangements have two
breakpoints per rearrangement (Figure S33 [DGAP187]21). Conse-
quently, it is expected that each of the two genomic-reference-
sequence alignments corresponds to one of two breakpoints in a
rearrangement sequence (Figures 2 and 3).
As an illustration of the process of aligning sequences of the re-
arrangements with BLAT, a hypothetical truly balanced simple
translocation case with t(1;8)(q23.3;q12.2) is presented in the
following steps (Figure 2) (additional hypothetical simple cases
akin to those in Figures 1B–1D are provided in Figures S1–S25):
1. Each of the rearrangement sequences is submitted with the
default settings (Genome: human; Assembly: Feb. 2009;
Query type: BLAT’s guess; Sort output: query, score; Output
type: hyperlink; and the sequence name can be specified as
‘‘>sequence name’’) (Figure 2, top right).
2. BLAT search results have 12 columns: ACTIONS, QUERY,
SCORE, START, END, QSIZE, IDENTITY, CHRO, STRAND,
START, END, and SPAN (Figure 2; Figures S28–S32). Herein,
the interpretations of rearrangement sequences are based on
these BLAT results.d ACTIONS:
Browser: a hyperlink providing a UCSC Genome
Browser view of the aligned sequence; it is used for
determining the chromosome bands of the breakpoint
regions.The AmeriDetails: a hyperlink providing a nucleotide-to-nucleo-
tide alignment of the query sequence to the genomic
reference sequence; this feature is used for sequences
where ‘‘span’’ and ‘‘score’’ values do not match and
‘‘identity’’ is not 100%.
d QUERY: the name of the submitted query; if a name is not
provided, the default display is ‘‘YourSeq.’’
d SCORE: a result that correlates with the number of
matching nucleotides in the query sequence to the refer-
ence sequence (for a detailed description, see ‘‘Replicating
web-based Blat percent identity and score calculations’’ in
the Web Resources).
d START: the position of the first nucleotide in the query
sequence aligned to the reference sequence.
d END: the position of the last nucleotide in the query
sequence aligned to the reference sequence.
d QSIZE: the total number of nucleotides in the query
sequence.
d IDENTITY: a result that correlates with the ratio of
matching nucleotide number in the aligned query
sequence to the total nucleotide number in the aligned
query sequence and the corresponding genomic refer-
ence sequence (for a detailed description, see ‘‘Replicating
web-based Blat percent identity and score calculations’’ in
the Web Resources).
d CHRO: the chromosome to which the query sequence
aligns.
d STRAND: the orientation (i.e., positive or negative strand)
of the query sequence relative to the positive strand ofcan Journal of Human Genetics 94, 695–709, May 1, 2014 697
Figure 3. Formatting the Rearrange-
ment Sequence on the Basis of BLAT
Search Results with BLA(S)T Output and
Next-Gen Cytogenetic Nomenclature
A representative chromosome diagram of
the aligned sequence is provided for Rear-
rangement_A (on der(1)). The BLA(S)T
Output indicates that breakage and reunion
occurred at 1q23.3, positive strand, nucleo-
tide 164,789,896 and at 8q12.2, positive
strand,nucleotide61,760,650 (top) (nucleo-
tide numbers with a purple background in
the table indicate the breakpoints, and for
illustration purposes, bracket locations in
the chromosome diagram are not relative
to actual chromosome positions). Next-
GenCytogeneticNomenclature isgenerated
with BLA(S)T Outputs for both of the rear-
rangement sequences. Note that the deriva-
tive chromosomes aredescribed frompter to
qter, and therefore the strand directions are
not included in the nomenclature (bottom).
698the genomic reference sequence. If the query strand is
positive, the start nucleotide of the query corresponds
to the start nucleotide of the aligned genomic reference
sequence and vice versa. However, if the query strand is
negative, the start nucleotide of the query corresponds
to the end nucleotide of the genomic reference sequence
and vice versa (Figures 6 and 7; Supplemental Data).
d START: the start nucleotide of the aligned genomic refer-
ence sequence.
d END: the end nucleotide of the aligned genomic refer-
ence sequence.
d SPAN: the span in nucleotides of the aligned genomic
reference sequence.
3. A single rearrangement sequence is expected to have two
genomic-reference-sequence alignments. In the event of
more than two alignments, the steps below should be fol-
lowed (Figure 2):
d The highest score alignment with the lowest query start
point is identified. Then, IDENTITY and SPAN are
checked. This sequence would represent the first aligned
part of the rearrangement (query) sequence, and the
breakpoint is identified on the basis of the strand orienta-
tion. In the case of t(1;8)(q23.3;q12.2), the first part of
Rearrangement_A (on der(1)) aligns to chromosome 1
(Figure 2, bottom right).
d The highest score alignment with the highest query end
point is identified. Then, IDENTITY and SPAN are
checked. This sequence would represent the second
aligned part of the rearrangement (query) sequence,
and the breakpoint is identified on the basis of the strand
orientation. In the case of t(1;8)(q23.3;q12.2), the second
part of Rearrangement_A (on der(1)) aligns to chromo-
some 8 (Figure 2, bottom right).The American Journal of Human Genetics 94, 695–709, May 1, 20144. Obtaining the true alignment
results of a single rearrangement
sequence does not provide informa-
tion for deletions or duplications
at the breakpoints of a transloca-
tion, an inversion, an insertion, or
a more complex rearrangementevent. For this information, alignment results of all rear-
rangement sequences involved in a single case should be
analyzed, and the continuity of breakpoint nucleotides
with corresponding sequence direction should be assessed
(Figures S26 and S27).
5. Details for the rearrangement sequences encompassing
additional events, such as an insertion or a nontemplated
sequence in the vicinity of the break and reunion, are pro-
vided in the Recommendations, as well as in the Supple-
mental Data.
Recommendations
ISCN 2013 should be followed both for the general princi-
ples of structural-rearrangement nomenclature and for
the use of cytogenetic symbols and abbreviated terms.13
Recommendations given below are suggested additions to
current guidelines and are based on the perspective of
DNA sequencing of structural chromosome abnormalities
derived from our efforts to describe sequencing results
from DGAP cases with apparently balanced rearrange-
ments20–24 and from tumor genomes with somatic rear-
rangements (Z.O., J.F.G., M.T., and C.C.M., unpublished
data).Wherever germane, ISCN2013 criteria are integrated.
Describing the Sequencing Method
The descriptive narrative or interpretation should include
the details of sequencing and confirmation method
(if applicable) and whether the sequencing represents the
entire genome (similar to ISCN 2013 for microarray
nomenclature).
Figure 4. Strand Direction and Identity of the Derivative Chro-
mosomeDesignation by the Chromosome Segment that Includes
the Centromere
(A) Structurally normal chromosomes.
(B) Pericentric inversion.
(C) q to q translocation.
(D) p to q translocation.
The dotted arrow indicates the positive (þ) strand direction of the
corresponding chromosome segment, and the thick arrow indi-
cates the positive strand direction of the chromosome.Choosing the Rearrangement-Sequence Strand to be
Reported
An example of the hypothetical t(1;8)(q23.3;q12.2) case
(akin to that in Figure 4C; the hypothetical inversion
and p to q translocation cases as in Figure 4B and 4D are
provided in Figures S5–S12) is as follows:der(1):
(þ) strand: 1pter/1q23.3::8q12.2/8qter
() strand: 8qter/8q12.2::1q23.3/1pterThe AmRearrangement_A should be reported with the use of the pos-
itive (þ) strand.
der(8):
(þ) strand: 8pter/8q12.2::1q23.3/1qter
() strand: 1qter/1q23.3::8q12.2/8pter
Rearrangement_B should be reported with the use of the
positive (þ) strand.
The DNAmolecule consists of two strands with opposite
directions. The positive (þ) strand of the genomic reference
sequence is designated as the sequence that goes from the
terminal end of the short arm (pter, the first nucleotide of
a chromosome) to the terminal end of the long arm (qter,
the last nucleotide of a chromosome), i.e., increasing
numbers of nucleotides, and vice versa is true for the nega-
tive () strand (Figure 4A). Although nucleotide numbers
increase starting from pter, band designations increase
numerically on both p and q arms by going outward from
the centromere. The orientations described herein are ac-
cording to nucleotide numbers that are in parallel with
the positive strand direction, but not necessarily with
band orientations.
ISCN 2013 describes a derivative chromosome as a structur-
ally rearranged chromosome that has an intact centro-
mere. We propose that directionality of the derivative
chromosome be defined by the directionality of the chro-
mosome segment that includes the centromere as present
in the human genomic reference sequence, regardless of
the directionality of other segments in the derivative chro-
mosome (Figure 4; Supplemental Data).
The rearrangement sequence should be reported with
the use of the positive strand of the derivative chromo-
some for ease of interpretation. Each rearrangement
sequence within a case is designated with a letter (e.g.,
Rearrangement_A, Rearrangement_B, ., Rearrangement_
AA, Rearrangement_AB, etc.). Assignment of letters to rear-
rangement sequences is random (although in alphabetic
order) because the letters are designated prior to interpreta-
tion of the rearrangement-sequence alignments.
BLA(S)T Output and the Rearrangement-Sequence
Format
BLA(S)T Output is not the final nomenclature for a chro-
mosome aberration; rather, it is the interpretation of an
individual rearrangement sequence. For constructing the
suggested Next-Gen Cytogenetic Nomenclature, the in-
formation provided in BLA(S)T Outputs of individual
rearrangement sequences are combined to describe the rear-
ranged chromosomes from pter to qter. If BLA(S)T Outputs
are listed separately fromthenomenclature (e.g., ina tabular
format), genome build numbers should be indicated.
The following is an example of the hypothetical
t(1;8)(q23.3;q12.2) case:
Rearrangement_A (on der(1)) (Figure 3, top)
BLA(S)T Output:
1q23.3(þ)(164,789,896)::8q12.2(þ)(61,760,650)erican Journal of Human Genetics 94, 695–709, May 1, 2014 699
Breakage and reunion have occurred at 1q23.3, positive
strand, nucleotide 164,789,896 and 8q12.2, positive
strand, nucleotide 61,760,650.
Rearrangement_B (on der(8))
BLA(S)T Output:
8q12.2(þ)(61,760,649)::1q23.3(þ)(164,789,897)
Breakage and reunion have occurred at 8q12.2, positive
strand, nucleotide 61,760,649 and 1q23.3, positive strand,
nucleotide 164,789,897.
The result of aligning a rearrangement sequence with
an alignment tool is referred to as ‘‘BLA(S)T Output’’
because it can be obtained with the use of either BLAT
or BLAST. In designating the BLA(S)T Output, three major
components are required: (1) details of the first aligned part
of the query, (2) break and reunion (::), and (3) details of the
second aligned part of the query. Each item within a compo-
nent is written without any spaces in between. In detail,
the BLA(S)T Output is recommended to be formulated
as follows (italic text in parentheses is used here for
description of the major components and is not part of
the format):
BLA(S)T Output: (first aligned part of the query)chromo-
some with band(strand)(breakpoint nucleotide number
on the corresponding genomic reference sequence)
(break and reunion)::(second aligned part of the query)chro-
mosome with band(strand)(the breakpoint nucleotide
number on the corresponding genomic reference
sequence)
At the discretion of the laboratory, the rearrangement
sequence may be color coded according to the determined
matching alignments; also, nucleotides may be numbered
and grouped in tens with 60 nucleotides in a row, as illus-
trated in Figures 3, 5, 6, and 7.
General Principles of Next-Gen Cytogenetic
Nomenclature
The following is an example of the hypothetical
t(1;8)(q23.3,q12.2) case (Figure 3, bottom):
Short system:
seq[GRCh37/hg19] t(1;8)(q23.3;q12.2)dn
Detailed system:
seq[GRCh37/hg19] t(1;8)(1pter/1q23.3(164,789,896)::
8q12.2(61,760,650)/8qter;8pter/8q12.2(61,760,649)::
1q23.3(164,789,897)/1qter)dn
Method
To specify that the results are obtained through
sequencing, ‘‘seq’’ should be included at the beginning of
the nomenclature (akin to using ‘‘arr’’ for microarrays
and ‘‘ish’’ for in situ hybridization [ISCN 2013]).
Reference-Genome Build
Both Genome Reference Consortium human build
(GRCh) and human genome (hg) numbers are included700 The American Journal of Human Genetics 94, 695–709, May 1, 2at the beginning of the nomenclature within brackets ([
]) and separated by a forward slash (/). Although ‘‘seq’’
precedes the bracket without a space, a space is present af-
ter the bracket (as in ISCN 2013 for microarray
nomenclature).
Order of Chromosomes
If one of the rearranged chromosomes is a sex chromo-
some, it is described first. Rearranged autosomes are listed
in numerical order.
Short and Detailed Systems
ISCN 2013 has two systems to designate structural ab-
normalities. Whereas the short system only provides
breakpoint band designations of involved chromosomes
(e.g., t(12;14)(q13;p11)), the detailed system describes
each of the rearranged chromosomes from pter to qter
(e.g., t(12;14)(12pter/12q13::14p11/14pter;12qter/
12q13::14p11/14qter). We recommend describing
each abnormality first by using the short system and
then by using the detailed system for Next-Gen Cytoge-
netic Nomenclature (and listing nucleotide numbers
only in the latter).
Nucleotide Numbers
Nucleotide numbers are specified within parentheses
after the band designation of the abnormal region. If
rearrangements are within a single chromosome (e.g.,
deletion, inversion, etc.), the chromosome number is not
specified in the band designation. Commas are recommen-
ded to facilitate reading nucleotides and are placed every
three digits for numbers comprising four or more
digits (similar to ISCN 2013 for ish and microarray
nomenclature).
Inheritance and Constitutionality
The inheritance symbols (dn [de novo], mat [maternal],
and pat [paternal]) are used after the description of the
rearrangement without a space after the last parenthesis.
If the inheritance symbol follows another abbreviation,
a space should be inserted (as in ISCN 2013).
When acquired and constitutional aberrations are
found in the same case, the latter is indicated by ‘‘c’’
directly after the designation of the constitutional abnor-
mality without a space. Note that if the inheritance is
known, ‘‘mat’’ or ‘‘pat’’ takes the place of the ‘‘c’’ (similar
to ISCN 2013).
Missing Whole-Genome Information
If a rearrangement sequence(s) is known without knowl-
edge of additional information of any other chromosomal
aberrations (e.g., from previous publication, capillary
sequencing confirmation of a single rearrangement
sequence, etc.), the BLA(S)T Output can be incorporated
after the description of the event, for example14 (Figure 5),
BLA(S)T Output:
8q24.21(þ)(128,749,16{0})::8q24.21(þ)(128,746,67{6})
This shows an approximately 2.5 kb direct duplication (if it
were inverted, the second alignment would be in the opposite
strand orientation) described in a previously reported case in
the vicinity of a t(2;8).014
Figure 5. Next-Gen Cytogenetic
Nomenclature of a Case with a Duplica-
tion on Chromosome 8 in the Vicinity of
a t(2;8)
When the rearrangement sequences are
not known genome-wide, the nomencla-
ture includes the BLA(S)T Output instead
of describing the derivative chromosome
frompter to qter; therefore, this nomencla-
ture includes the strand directions (curly
brackets indicate homology, and nucleo-
tide numbers with a purple background in
the table indicate the breakpoints).Next-Gen Cytogenetic Nomenclature:
seq[GRCh37/hg19] dup(8)(q24.21(þ)(128,749,16{0})::
q24.21(þ)(128,746,67{6}))
Because the additional rearrangement sequences are not
provided and the sequencing is not genome-wide, the nomen-
clature includes the BLA(S)T Output only for the duplication
event with known sequence instead of describing der(8) from
pter to qter. For the interpretation of homologies and curly
brackets, see ‘‘Homology.’’
Combining Sequencing Results with Other
Cytogenetic Methods
To separate various cytogenetic observations, ISCN 2013
recommends using a period followed by the symbol of
the method (ish, arr, etc.) and the result of the specified
method. The G-banded karyotype is specified first without
a symbol. The same approach can be applied while
combining sequencing results with other cytogenetic
methods.
Examples are as follows:
Short system:
46,XX,t(5;10)(p13.3;q21.1)dn.seq[GRCh37/hg19] t(5;10)
(p13.3;q21.3)dn
Detailed system:
46,XX,t(5;10)(p13.3;q21.1)dn.seq[GRCh37/hg19] t(5;10)
(10qter/10q21.3(67,539,997)::5p13.3(29,658,440)/5qter;
10pter/10q21.3(67,539,990)::5p13.3(29,658,426)/5pter)dn
This shows whole-genome sequencing detecting a translo-
cation observed in the G-banded karyotype. Note that the
cytogenetic-band assignments are derived from G-banded
chromosomes and that the sequencing-band assignments
are derived from genome browsers; therefore, they are
not always concordant with each other (as in ISCN
2013 for microarray nomenclature). In addition, the
breakpoint nucleotides of 67,539,990 and 67,539,997
and their sequence directions indicate a 6 bp deletion on
chromosome 10, and the breakpoint nucleotides of
29,658,426 and 29,658,440 and their sequence direc-The American Journal of Human Gtions indicate a 13 bp deletion on
chromosome 5. For the sake of
simplicity, in the detailed system,
the short description of the G-
banded karyotype is combined withthe detailed description of the Next-Gen Cytogenetic
Nomenclature.
Short system:
ish t(9;22)(ABL1þ,BCRþ;BCRþ,ABL1þ)[20]
.seq[GRCh37/hg19] t(9;22)(q34.1;q11.23)
Detailed system:
ish t(9;22)(ABL1þ,BCRþ;BCRþ,ABL1þ)[20]
.seq[GRCh37/hg19] t(9;22)(9pter/9q34.1
(133,643,307)::22q11.23(23,632,613)/22qter;
22pter/22q11.23(23,632,612)::9q34.1
(133,643,308)/9qter)
This shows in situ hybridization and sequencing detecting a
t(9;22).
Short system:
46,XX.arr[hg19] 12p12.1(21,340,001–23,500,000)31
.seq[GRCh37/hg19] del(12)(p12.1p12.1)
Detailed system:
46,XX.arr[hg19] 12p12.1(21,340,001–23,500,000)31
.seq[GRCh37/hg19] del(12)(pter/p12.1(21,340,000)::
p12.1(23,500,001)/qter)
This shows microarray and sequencing detecting a deletion
that was not observed in the G-banded karyotype.
Homologous Chromosomes
If a rearrangement involves homologous chromosomes,
one of the chromosome numerals should be underlined,
for example,
seq[GRCh37/hg19] t(9;9)(9qter/9q22.33(102,425,452)::
9p21.2(26,393,002)/9qter;9pter/9q22.33(102,425,451)::
9p21.2(26,393,001)/9pter)
This shows a translocation between the short arm of chro-
mosome 9 and the long arm of its homolog.
Homology
Some nucleotide(s) might belong to either chromosome at
the breakpoints (i.e., a homology), and thus it is not
possible to determine their chromosome of origin. The
smallest digits of the nucleotide number best specifyingenetics 94, 695–709, May 1, 2014 701
the homology are placed in curly brackets ({ }), and the first
and last nucleotides are separated by a dash (–). The first
and last nucleotides are placed in the order in which
they occur in the rearranged sequence and not in numeri-
cal order. If a segment is of sufficient length to change the
band assignment, the start and end bands are included
without a dash, e.g., 4q31.3(151,513,239–151,513,560)
versus 4q31.3q32.1(151,513,239–156,815,165) as in
ISCN 2013 for microarray nomenclature.
Examples are as follows:
seq[GRCh37/hg19] der(5)(10qter/10q21.3
(67,539,99{7–5})::5p13.3(29,658,44{0–2})/5qter)
An unbalanced translocation between the short arm of chro-
mosome 5 and the long arm of chromosome 10 results in a
der(5) with a 3 nt homology at the break and reunion.
seq[GRCh37/hg19] der(5)(10qter/10q21.3
(67,539,9{97–85})::5p13.3(29,658,4{40–52})/5qter)
A der(5) has a 13 nt homology at the break and reunion.
seq[GRCh37/hg19] der(5)(10qter/10q21.3
(67,5{40,000–39,997})::5p13.3(29,658,44{0–3})/5qter)
A der(5) has a 4 nt homology at the break and reunion.
Nontemplated Sequence and CNVs
Nucleotide(s) that do not align to a reference chromosome
are defined as nontemplated sequence. Note that BLAT lists
the most relevant results to identify the complete
rearrangement sequence; therefore, a sequence that appears
as nontemplated in the BLAT results of a rearrangement
sequencemight align to a reference chromosomewhensub-
mitted separately (20 is the minimum number of nucleo-
tides for BLATuse), or itmight be a small repeat of sequence
in the vicinity of the breakpoint.
In order to avoid an unwieldy description, we provide
only BLA(S)T Outputs of single rearrangement sequences
in the examples. Note that for nontemplated sequences,
CNVs, and homologies, the same rules apply to both
BLA(S)T Output andNext-Gen Cytogenetic Nomenclature.
Nontemplated Sequence Other Than Single-Nucleotide Change
or Mutation
If the nontemplated nucleotide represents a SNP or a
mutation, current guidelines for reporting such alterations
(e.g., from the HumanGenome Variation Society) are used.
Otherwise, the unmapped nucleotide(s) should be
reported after the break and reunion symbol (::) and
should be followed by another break and reunion symbol
(::) without any space. If the nontemplated sequence is
longer than 50 nucleotides, then the first and last three
nucleotides of the nontemplated sequence may be pro-
vided in the nomenclature after an ellipsis (.), followed
by the number of nucleotides in curly brackets ({ }). The
complete nontemplated sequence needs to be included
in the report for future reference.
Examples are as follows:
11q14.2(þ)(87,665,449)::TTC::2q32.1()(186,039,460)
A nontemplated sequence of three nucleotides (TTC) is
located between the breakpoints.702 The American Journal of Human Genetics 94, 695–709, May 1, 211q14.2(þ)(87,665,449)::TTC.ACG{75}::
2q32.1()(186,039,460)
A nontemplated sequence of 75 nucleotides (starting with
TTC and ending with ACG) is located between the break-
points.
Nontemplated Sequence as a Repeat
At thediscretionof the reporting laboratory, itmaybedeter-
mined whether the nontemplated sequence is a repeat of
sequence in the vicinity of the breakpoint. A practical way
to detect repeats is to align the nontemplated sequence
(query) to the rearrangement sequence (subject) with
BLAST, especially if the nontemplated sequence is fewer
than 20 nucleotides (see examples under ‘‘CNVs’’ below).
CNVs
When CNVs are reported, the range should be written in
parentheses in sequential order (not in numerical order)
and separated by a dash (–). If the segment is of sufficient
length to change the band assignment, the start and end
chromosome bands are included without a dash. If the re-
peats are identical and consecutive in the sequence, the
number of repeats should be indicated after a multiplica-
tion sign (3) following the parenthesis for the nucleotide
designation without a space (as in ISCN 2013 for microar-
ray nomenclature).
Examples are as follows:
This is the alignment result of a rearrangement sequence
on der(5) of a t(1;5)(p22.3;q14.3) (Figure 6A; Figure S49
[DGAP131]21):
BLA(S)T Output: 5q14.3(þ)(88,829,562)::
GTCTCCAGGA::1p22.3()(86,157,132)
or
BLA(S)T Output: 5q14.3(þ)(88,829,562)::
5q14.3(88,829,550–88,829,558)::A::
1p22.3()(86,157,132)
Nucleotides 39–47 of the rearrangement (query) sequence are
the repeat of nucleotides 26–34 of the rearrangement (query)
sequence and nucleotides 88,829,550–88,829,558 of the
chromosome 5 reference sequence. Nucleotide 48 of the rear-
rangement (query) sequence is not part of the repeat; there-
fore, it is written as ‘‘A.’’
This is the alignment result of a rearrangement sequence
from an inv(8)(q11.21q24.33) (Figure 6B; DGAP247, Z.O.,
J.F.G., M.T., and C.C.M., unpublished data):
BLA(S)T Output: 8q11.21()(51,889,502)::
TATTCTTTATTCTTTATTCT::8q24.23(þ)(136,495,815)
or
BLA(S)T Output: 8q11.21()(51,889,502)::
8q24.23(136,495,816–136,495,822)34::
8q24.23(þ)(136,495,823)
Nucleotides 89–109 of the rearrangement (query) sequence
are three repeats of nucleotides 110–116 of the rearrange-
ment (query) sequence and nucleotides 136,495,816–
136,495,822 of the chromosome 8 reference sequence.014
Figure 6. BLA(S)T Outputs for Nontemplated Sequences
The nontemplated sequence of t(1;5)(p22.3;q14.3) on der(5) represents a repeat of nine nucleotides and an additional A nucleotide (A).
The nontemplated sequence from inv(8)(q11.21q24.33) represents a quadruple repeat of seven nucleotides (B). In the rearrangement-
sequence formats, nontemplated sequences are indicated in black, and repeated sequences are highlighted within parentheses. In the
tables, nucleotide numbers with a purple background indicate the breakpoints.Note that nucleotide 109 (T) of the query is interpreted to be
included in the nontemplated repeat region for the least
complicated explanation of the repeat at the break and
reunion. Therefore, the BLA(S)T Output of the nucleotide
of the last part of the query is revised from nucleotide
136,495,815 to 136,495,816 of the reference sequence
when the repeat is reported.
When the nontemplated sequence (TATTCTTTATTCTT
TATTCT) is aligned with BLAT, it results in an alignment
on chromosome 7. Considering that there is no indication
of involvement of chromosome 7 on the basis of either
G-banded karyotype or sequencing data, this scenario is
interpreted to be incorrect.
The following is a hypothetical case with a CNV:
seq[GRCh37/hg19] dup(8)(pter/q11.21(51,889,502)::
q11.21q24.23(51,889,503–136,495,822)32::
q24.23(136,495,823)/qter)The AmThis case has a duplication of the indicated region. Note
that in contrast to the array or in situ hybridization
nomenclature, the nomenclature here does not include the
copy on the unaltered chromosome 8 in this multiplication
sign.
Nontemplated Sequence as a Chromosome Segment Involved in
a Rearrangement
If a direct repeat is not identified, another consideration is
whether the nontemplated sequence is a chromosome
segment (e.g., an inverted end or inverted repeat) that
might be involved in a rearrangement. Additional cytoge-
netic observations (e.g., G-banded karyotype or meta-
phase ish) might be helpful for the interpretation of
such results.
The following is an example of a rearrangement
sequence on a der(8) of a complex case with more
than two rearrangement sequences, including a translo-
cation between the long arms of chromosomes 3 and 8erican Journal of Human Genetics 94, 695–709, May 1, 2014 703
Figure 7. BLA(S)T Output for an Inverted Repeat as a Nontemplated Sequence
In a complex case with t(3;8)(q25.32;q24.21), the nontemplated sequence and nucleotides 663–684 of the rearrangement sequence
correspond to nucleotides 128,564,042–128,564,063 of the chromosome 8 reference sequence in an opposite orientation (in the table,
nucleotide numbers with a purple background indicate the breakpoints) (A). This result is obtained through BLAST alignment of the
nontemplated sequence to the rearrangement sequence, revealing an identical match between the two sequences, excluding the self-
alignment (arrows show the opposite strand directions) (B).(Figure 7; Z.O., J.F.G., M.T., and C.C.M., unpublished
data):
BLA(S)T Output: 3q25.32(þ)(158,573,186)::
ACCATGTTTGTAATTTCATTGC::
8q24.21()(128,564,075)
or
BLA(S)T Output: 3q25.32(þ)(158,573,186)::
8q24.21(128,564,042–128,564,063)::
8q24.21()(128,564,075)704 The American Journal of Human Genetics 94, 695–709, May 1, 2014The nontemplated sequence is an inverted repeat of
the designated nucleotides. This inverted repeat is
revealed through BLAT alignment of the nontemplated
sequence (because the query size is larger than 20
nucleotides). This result is also confirmed through
BLAST alignment of the nontemplated sequence (AC
CATGTTTGTAATTTCATTGC) as the ‘‘query’’ and of the
complete rearrangement sequence as the ‘‘subject’’ (Figure 7B).
Note that in a simple translocation between the long arms of
two chromosomes, both of the aligned sequences are expected
to have the same orientation (Figure 4C). However, this case
is a complex case with more than two rearrangement se-
quences; therefore, the orientations of the two aligned se-
quences are in opposite directions.
Repetitive Elements
If the rearrangement sequence aligns to a repetitive
element with multiple identical matches at different loca-
tions, in addition to a comment in the narrative report,
two approaches may be followed at the discretion of the
laboratory:
1. When supported by the other breakpoints and/or
cytogenetic methods, the reference chromosome
and nucleotide numbers of the repetitive element
may be chosen on the basis of the alignment that
is on the relevant chromosome location (band
and/or nucleotide level).
2. If the alignment is ambiguous and one region is not
more relevant to the rearrangement than the others,
the repetitive region may be reported as a nontem-
plated sequence (see ‘‘Nontemplated Sequence Other
Than Single-Nucleotide Change or Mutation’’).
Uncertain Breakpoint Localization
An approximation sign (~) can be used for rearrangements
estimated to be within a nucleotide range, but not able to
be delineated to the single-nucleotide level. Nucleotide
ranges are listed in the order of the sequence.
Examples are as follows:
seq[GRCh37/hg19] der(3)(3pter/3q25.32
(158,573,186)::8q24.21(128,534,000~128,546,000)/8qter)
An unbalanced translocation between the long arms of chro-
mosomes 3 and 8 results in a der(3) with an estimated nucle-
otide range for the breakpoint on chromosome 8.
seq[GRCh37/hg19] der(3)(8qter/8q24.21
(128,546,000~128,534,000)::3q25.32(158,573,186)/3qter)
An unbalanced translocation between the short arm of chro-
mosome 3 and the long arm of chromosome 8 results in a
der(3) with an estimated nucleotide range for the breakpoint
on chromosome 8.
seq[GRCh37/hg19] der(3)(3pter/3q25.32
(158,573,186~)::8q24.21(128,534,288~)/8qter)
An unbalanced translocation between the long arms of
chromosomes 3 and 8 results in a der(3) with an estimated
nucleotide number for both of the breakpoints because the
rearrangement sequence is not able to be confirmed with
capillary sequencing.
Complex Cases
The symbol ‘‘cx’’ (similar to ISCN 2013) can be used for
three or more complex rearrangements across at least two
chromosomes. Note that there is no space when a symbol
or abbreviation precedes or follows a parenthesis; there-
fore, the parenthesis for the involved chromosomes imme-
diately follows the bracket, for example,The Amseq[GRCh37/hg19](2,3,8)cx
These complex rearrangements involve chromosomes 2, 3,
and 8.
Chromothripsis
The symbol ‘‘cth’’ can be used for chromothripsis referring
to complex events along a chromosome or chromosome
segment (similar to ISCN 2013 for complex array results)
and is recommended for three or more rearrangements,
for example,
seq[GRCh37/hg19] 8q13.3q21.11
(72,332,704–76,296,139)cth
Sequencing reveals multiple events in chromosome 8 between
bands q13.3 and q21.1 and nucleotides 72,332,704 and
76,296,139.
Constructing Derivative Chromosomes from pter to qter
If possible, in the detailed system, each of the derivative
chromosomes should be described from pter to qter, as
recommended in the general principles (see ‘‘General
Principles of Next-Gen Cytogenetic Nomenclature’’). This
description would not only provide a cytogenetic point
of view for these complex rearrangements but also assist
in understanding possible position effects (i.e., which
chromosome segments, genes, or regulatory elements
are in proximity on the derivative chromosomes). The
nomenclature begins with seq and the GRCh and hg
numbers, followed by the rearrangement type (cx or cth)
and then a comma with a description of each derivative
chromosome (see Figure S33 [DGAP187]21 for detailed
instructions).
Here is an example (Figure S33 [DGAP187]21):eriShort system:
46,XX,t(6;13)(q21;q32)dn.seq[GRCh37/hg19](6,13)cx,
der(6)t(6;13)(q14.3;q31.1)dn,der(13)t(6;13)inv(6)
(q14.3q14.3)dn
Detailed system:
46,XX,t(6;13)(q21;q32)dn.seq[GRCh37/hg19](6,13)cx,
der(6)(6pter/6q14.3(85,897,870)::A::13q31.1(80,659,609)
/13qter)dn,der(13)(13pter/13q31.1(80,659,606)::6q14.3
(85,900,543–86,488,29{1})::6q14.3(85,900,54{0}–
85,897,899)::6q14.3(93,909,993)/6qter)dn
This is a complex case with four rearrangements (one in
der(6) and three in der(13)). The der(6) is derived from a
translocation between 6q14.3 and 13q31.1. The der(13)
has the same translocation, in addition to an inversion at
6q14.3. There is a nontemplated nucleotide in the der(6)
and a single-nucleotide homology in the der(13). Note that
in addition to multiple base-pair-scale nucleotide imbal-
ances, there is an approximately 7.4 Mb deletion between
nucleotides 86,488,291 and 93,909,993 because the
segment ending with 6q14.3 (86,488,29{1}) going toward
the centromere is the closest to the segment starting with
6q14.3 (93,909,993) going toward qter on the basis of the
reference chromosome 6 sequence.can Journal of Human Genetics 94, 695–709, May 1, 2014 705
Describing Rearrangements with BLA(S)T Outputs
If it is not possible to construct derivative chromosomes
frompter to qter (e.g., because of toomany complex events,
missing breakpoints, etc.) or as an alternative, the BLA(S)T
Outputs of the rearrangement sequences may be used to
describe individual breakpoints and are separated by
commas. BLA(S)T Outputs are listed starting with sex chro-
mosomes, followed by autosomes; breakpoint nucleotides
of the first aligned part of the query are provided in refer-
ence-chromosome sequential order. Nomenclature begins
with seq and the GRCh and hg numbers, followed by the
abbreviated rearrangement description (cx or cth). The in-
heritance symbol at the end of a string indicates that the
whole string has the provided inheritance (similar to
ISCN 2013 for microarray nomenclature).
Here is an example (Figure S33 [DGAP187]21):Short system:
46,XX,t(6;13)(q21;q32)dn.seq[GRCh37/hg19](6,13)cx dn
Detailed system:
46,XX,t(6;13)(q21;q32)dn.seq[GRCh37/hg19](6,13)cx,
6q14.3(þ)(85,897,870)::A::13q31.1(þ)(80,659,609),6q14.3
()(85,897,899)::6q14.3(þ)(93,909,993),6q14.3(þ)
(85,900,54{0})::6q14.3()(86,488,29{1}),6q14.3()
(85,900,543)::13q31.1()(80,659,606)dn
This is the same complex case described in the previous
example (DGAP18721). Instead of describing the derivative
chromosomes, it lists all of the BLA(S)T Outputs (separated
by commas) in the reference-chromosome sequential order of
the first parts of the BLA(S)T Outputs. The BLA(S)T Output
starting with 6q14.3(þ)(85,897,870) is followed by the
BLA(S)T Output starting with 6q14.3()(85,897,899),
then 6q14.3(þ)(85,900,540), and lastly 6q14.3()
(85,900,543). For preserving reference-chromosome sequen-
tial order, the reverse complement of a BLA(S)T Output
can be used (e.g., 6q14.3()(85,900,543)::13q31.1()
(80,659,606) vs. 13q31.1(þ)(80,659,606)::6q14.3(þ)
(85,900,543); see Figure S33 [DGAP187]21 for more de-
tails). The ‘‘dn’’ at the end of the string indicates that the
whole string is de novo. Note that in the short system, the
case is only described as ‘‘cx’’ because the derivative chromo-
somes are not described from pter to qter.
In highly complex cases, it might be convenient to
display results by using Next-Gen Cytogenetic Nomencla-
ture in tabular format instead of a string (Table S1) (similar
to ISCN 2013 for microarray nomenclature).
Further Examples and BOSToN
DGAP represents a large collection of individuals with
abnormal phenotypes and constitutional balanced chro-
mosome rearrangements. Next-Gen Cytogenetic Nomen-
clature of a selection of previously published sequenced
DGAP cases and of additional hypothetical simple cases
is provided in Table S2 and the Supplemental Data.
To facilitate implementationof thisnomenclature,weare
developing a program entitled BOSToN (BLA(S)T Output706 The American Journal of Human Genetics 94, 695–709, May 1, 2Sequence Tool of Nomenclature) in the spirit of previous
landmark conferences in cytogenetics (e.g., Denver
[1960], London [1963], Chicago [1966], and Paris [1971,
1975]). BOSToN is a web-based program that employs the
Next-Gen Cytogenetic Nomenclature recommendations.
The goal of BOSToN is to obtain the BLA(S)TOutputs, result
tables, and Next-Gen Cytogenetic Nomenclature by
entering FASTA format rearrangement sequences. All data
are currently acquired fromBLAST, and therefore, the result
tables presented in BOSToN are in correlation with BLAST
display and provide the BLAST score, expectation value,
identity, gap, chromosome number, direction, subject
(reference chromosome sequence) start and end, query
(submitted rearrangement sequence) start and end, and
total numbers. An illustrative version of BOSToN, along
with a list ofDGAPcases and their sequences fordemonstra-
tion of the tool, is embedded in a publicly available website
(see Web Resources). For use in clinical or research labora-
tories, a variety of improvements in BOSToN are planned.Discussion
It has become increasingly evident that delineating struc-
tural chromosome rearrangements is of clinical signifi-
cance,20–31 and sequencing such aberrations has already
enteredclinicalpractice.20,31,36,37The lackof aconsensussys-
tem to describe these rearrangements at the molecular level
could lead tomiscommunication of clinical and research re-
sults. We suggest Next-Gen Cytogenetic Nomenclature, a
system analogous with ISCN 2013, and are developing
BOSToN as an online tool to facilitate its implementation.
Despite the current necessity of a nomenclature system,
sequencing results of structural rearrangements have
been available since the 1980s. The example provided in
‘‘Missing Whole-Genome Information’’ represents an
illustration of applying Next-Gen Cytogenetic Nomencla-
ture to results obtainedwithhistorical sequencingmethods
in a Burkitt lymphoma reported in 1984.14 Current next-
generation sequencing technologies are able to provide
genome-wide information for both unbalanced and
balanced structural rearrangements. Consequently, the
suggested nomenclature is designed to describe both rear-
rangement types. Although unbalanced rearrangements
might be the result of a single structural-rearrangement
event (e.g., deletion, duplication, addition, amplification,
or a single derivative of a simple translocation), they might
also result from gains or losses accompanying transloca-
tions or inversions or even more complex rearrangements.
For the former, the imbalancemight be interpreted through
the symbolic description of the event (e.g., the description
of a duplication case would start with ‘‘dup’’ and would
therefore imply the imbalance). For the latter, the direction
of the aligned sequences, along with the continuity of the
breakpoint nucleotides of the rearrangements based on
the reference chromosome sequence, needs to be assessed
(as described in Figures S26 and S27).014
With rapid advances in genomic technologies, the
exponential increase in sequencing data for structural chro-
mosome aberrations introduces new concepts in genetics,
such as chromothripsis. Next-Gen Cytogenetic Nomencla-
ture can also be applied to complex chromosomal
rearrangements, including chromothripsis. Nomenclature
for sequencing results of a cancer cell line reported in
the first publication of chromothripsis29 (seq[NCBI36/
hg18] 5p15.33q34(1,391,571–167,283,889)cth) is listed in
Table S1.
Evolving knowledge generated from next-generation
sequencing will most likely require ongoing modifications
to the nomenclature described herein. One such issue is
the human genomic variant regions that are described as
‘‘alternate loci (alt loci)’’ by the Genome Reference Con-
sortium. The recently released GRCh38 has 261 alt loci
scaffolds in 35 alternate assembly units. A structural rear-
rangement within the region of an alt locus or the presence
of the alt locus in an individual might be of clinical impor-
tance in assessing the pathogenicity of a rearrangement. In
such instances, a possible consideration is to add the
extension of alt loci assembly units after the GRCh build
number and separate them with an underscore (e.g.,
[GRCh37_ALT_REF_LOCI_1/hg19] represents the use of
the first alternate sequence on chromosome 6 [major histo-
compatibility complex region] in GRCh37). Another
issue is the combination of the nomenclature of sequence
variants other than structural rearrangements (e.g., single-
nucleotide substitutions) and the structural chromosome
rearrangements, given that both can be obtained by
next-generation sequencing.36 Another example of a
future consideration is describing the results of structural
aberrations at the RNA and protein levels, or in the mito-
chondrial genome.
The suggested nomenclature described herein is de-
signed to provide an objective system to explain the
structural rearrangements at a molecular level. Nonethe-
less, similar to microarray nomenclature described in
ISCN 2013, it does not inform the clinical significance
of these aberrations. Considering the establishment of
chromosome microarrays in clinical practice,38–40 the
pathogenic significance of the sequencing results of
structural chromosome aberrations resulting in copy-
number changes (e.g., deletions, duplications, etc.) can
be interpreted akin to the evaluation of microarray re-
sults of such rearrangements with the use of the
following categories: (1) pathogenic variants, (2) variants
of uncertain clinical significance, and (3) benign variants.
The clinical significance of balanced chromosome rear-
rangements (e.g., translocations and inversions) has not
been extensively compared to that of CNVs or muta-
tions. Therefore, currently available resources (e.g., publi-
cations, databases, etc.) for CNVs or mutations can be
combined for the interpretation of the balanced struc-
tural rearrangements through evaluating the association
of the disrupted regions and/or genes with an abnormal
phenotype, as illustrated in previous DGAP publica-The Amtions.20–24 In addition, the data for individuals with or
without an abnormal phenotype with apparently
balanced chromosome rearrangements are incorporated
into some existing databases (e.g., DGV41 and
DECIPHER42), and new databases (e.g., InvFEST43) are
emerging specifically for these rearrangements. On the
basis of the evidence gathered from these resources, the
clinical significance of balanced rearrangements can be
assessed given the following scenarios (in increasing or-
der of potential concern): disruption of nonpathogenic
regions observed in individuals without a presumed rele-
vant clinical phenotype, disruption of nongenic regions
of uncertain clinical significance, disruption of a single
gene or regulatory region of uncertain clinical signifi-
cance, disruption of a single pathogenic region (reces-
sive), disruption of a single pathogenic region(dominant),
and so on. These interpretations are subject to change with
additional studies, as observed in the clinical evaluation of
microarray results.44 However, adding a summarized ‘‘inter-
pretation table’’ including the relevant information (e.g.,
disruption of a pathogenic region, a list of involved genes
or at least genes known to be pathogenic, evidence based
on previously published cases, etc.) might be valuable for
healthcare providers.
Next-Gen Cytogenetic Nomenclature provides a path for
describing sequencing data of constitutional and acquired
structural rearrangements obtained through historical and
current sequencing techniques, thus facilitating the
communication of sequencing results. The interpretation
of structural rearrangements detected by sequencing and
their clinical significance can be complex, warranting
further development of computational algorithms to assist
with this process.Supplemental Data
Supplemental Data include 53 figures and two tables and can be
found with this article online at http://dx.doi.org/10.1016/j.
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Web Resources
The URLs for data presented herein are as follows:
BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE¼
BlastSearch&PROG_DEF¼blastn&BLAST_PROG_DEF¼megaBlast
&BLAST_SPEC¼blast2seq
BLA(S)T Output Sequence Tool of Nomenclature (BOSToN),
http://boston.bwh.harvard.edu/
Database of Genomic Variants (DGV), http://dgv.tcag.ca/dgv/app/
home
DECIPHER, http://decipher.sanger.ac.uk
Developmental Genome Anatomy Project (DGAP), http://www.
bwhpathology.org/dgap/
GRCh38, http://www.ncbi.nlm.nih.gov/projects/genome/
assembly/grc/human/
Human Genome Variation Society, http://www.hgvs.org/
mutnomen/
InvFEST: Human Polymorphic Inversion Database, http://
invfestdb.uab.cat/
Replicating web-based Blat percent identity and score calculations,
http://genome.ucsc.edu/FAQ/FAQblat.html#blat4
UCSC Genome Browser, http://genome.ucsc.eduReferences
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